Regeneron Pharmaceuticals, Inc. (REGN) — Fair Value Analysis

Base-case fair value (P50): $672.80 · Current price: $698.25 · Verdict: Fairly Valued

The Verdict on REGN

Based on extensive Monte Carlo simulations, Regeneron Pharmaceuticals (REGN) appears Fairly Valued at its current market price of $698.25. Our analysis, which models thousands of forward scenarios, indicates a median fair value (P50) of $672.80. This suggests a modest -3.6% against the current price, aligning with a neutral valuation outlook. For investors scrutinizing REGN, this signals that the stock is trading near its intrinsic value derived from a probabilistic framework, implying limited immediate arbitrage opportunities based purely on a fair value assessment.

How REGN stacks up against Healthcare

REGN's position within the Healthcare sector merits attention, particularly concerning its "weak" quality tier. This quality rating, which assesses the company's operational and financial health relative to its peers, suggests underlying factors that influence its valuation profile. While our Monte Carlo simulations provide a robust fair value estimate of $672.80, the "weak" quality tier implies that REGN might face challenges or possess characteristics that differentiate it from higher-quality sector counterparts. This qualitative dimension is critical when interpreting the quantitative outputs, such as the -3.6% and the current trading price of $698.25.

What this means for investors

For investors considering REGN, the current assessment of Fairly Valued with a -3.6% implies a balanced risk-reward profile from a fair value perspective. The stock is not presenting a compelling discount or premium according to our simulations. The "weak" quality tier suggests that while the stock is trading near its $672.80 fair value, investors should remain aware of potential operational or financial headwinds within the Healthcare sector. To gain deeper insight into REGN's full valuation spectrum, including specific bear and bull case scenarios, sign up for FairCurve to see the complete probability distribution and track REGN's fair value as new fundamentals are released.